Summary of findings: levodopa vs other dopamine agonists: Adverse effects (drop‐outs due to adverse effects4)
Summary of findings: levodopa probably leads to lower number of drop outs due to adverse events compared with other dopamine agonists (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings: levodopa vs other dopamine agonists Number of drop outs due to adverse events · patients with restless legs syndrome Summary of findings: levodopa probably leads to lower number of drop outs due to adverse events compared with other dopamine agonists (moderate certainty). Levodopa for the treatment of restless legs syndrome (2011) · Cochrane Headline outcomes only | OR 0.59 | 3 studies · 504 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Levodopa for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.